CNS Pharma faces Nasdaq delisting for bid price deficiency; hearing Nov 5

CNS Pharmaceuticals, Inc.

Received Nasdaq notice on Sept 12, 2024, for failing minimum $1.00 bid price for 30 consecutive days.
Ineligible for 180-day cure period due to reverse stock splits >250:1 cumulative ratio in prior two years.
Hearing before Nasdaq Panel scheduled for Nov 5, 2024; automatically stays suspension or delisting pending hearing.
No assurance that Panel will grant an additional compliance extension beyond the hearing date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.